Ishares Iv Public Etf Performance
| ISHFF Etf | USD 101.33 0.35 0.35% |
The etf retains a Market Volatility (i.e., Beta) of 0.0314, which attests to not very significant fluctuations relative to the market. As returns on the market increase, IShares IV's returns are expected to increase less than the market. However, during the bear market, the loss of holding IShares IV is expected to be smaller as well.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in iShares IV Public are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite nearly stable technical and fundamental indicators, IShares IV is not utilizing all of its potentials. The recent stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
IShares |
IShares IV Relative Risk vs. Return Landscape
If you would invest 10,053 in iShares IV Public on October 19, 2025 and sell it today you would earn a total of 80.00 from holding iShares IV Public or generate 0.8% return on investment over 90 days. iShares IV Public is currently producing 0.014% returns and takes up 0.4888% volatility of returns over 90 trading days. Put another way, 4% of traded pink sheets are less volatile than IShares, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
IShares IV Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for IShares IV's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as iShares IV Public, and traders can use it to determine the average amount a IShares IV's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0286
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ISHFF |
Based on monthly moving average IShares IV is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of IShares IV by adding it to a well-diversified portfolio.
IShares IV Fundamentals Growth
IShares Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of IShares IV, and IShares IV fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on IShares Pink Sheet performance.
About IShares IV Performance
By analyzing IShares IV's fundamental ratios, stakeholders can gain valuable insights into IShares IV's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if IShares IV has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if IShares IV has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
iShares IV Public Limited Company - iShares Short Duration Corporate Bond UCITS ETF is an exchange traded fund launched by BlackRock Asset Management Ireland Limited. It seeks to replicate the performance of the Markit iBoxx USD Liquid Investment Grade 0-5 Index, by employing representative sampling methodology. iShares IV Public Limited Company - iShares Short Duration Corporate Bond UCITS ETF was formed on October 16, 2013 and is domiciled in Ireland. Ishares Short is traded on OTC Exchange in the United States.